Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Los términos de búsqueda han de ser en inglés.

A Spanish research center offers a synthetic hydrogel for immunotherapy and 3D printing

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOES20200713001
Publicado:
15/07/2020
Caducidad:
16/07/2021
Resumen:
A Spanish biomedical research networking center has developed a novel 3D (bio)printable hydrogel. They have also created the method for producing it and its use in T-cell culture for immunotherapies (particularly in cancer). The biomedical center is looking to establish license, research cooperation, or joint venture agreements.

Details

Tittle:
A Spanish research center offers a synthetic hydrogel for immunotherapy and 3D printing
Summary:
A Spanish biomedical research networking center has developed a novel 3D (bio)printable hydrogel. They have also created the method for producing it and its use in T-cell culture for immunotherapies (particularly in cancer). The biomedical center is looking to establish license, research cooperation, or joint venture agreements.
Description:
This research networking center gathers some of the main Spanish research groups in biomedicine, located in more than 100 institutions like universities, hospitals, and technological centers distributed around the country.
Immunotherapy is a medical strategy that offers a different approach to chemotherapy, radiation, and surgery in the treatment of diseases, particularly in cancer. Immunotherapy is based on employing and reinforcing the immune system of patients. The immune system protects the organisms against disease, distinguishing between self and non-self. However, cancer appears from the organism own cells, and it creates a tumor microenvironment with immune evasion and immunosuppression signals capable of avoiding the immune response. The main objective of immunotherapy is to develop different strategies able to surpass cancer immunosuppression methods, detect and eliminate malignant cells without damaging healthy tissues.
The present invention discloses a novel 3D (bio)printable hydrogel, the method for producing it and its use in T cell culture for immunotherapies. This hydrogel is based on a functionalized poly(ethylene)glycol (PEG) polymer covalently combined with heparin (Hep), which is loaded with at least one immune molecule.
The Spanish research center seeks industrial o research partners from the pharmaceutical or biotech sector to establish license, research cooperation, or joint venture agreements. The aim of this collaboration will be to perform proof of concept and drug testing.
Advantages and Innovations:
The PEG-Hep hydrogel was combined with different positively charged biomolecules such as cytokines and cell-adhesive molecules to provide customized hydrogel scaffolds.
These scaffolds are able to mimic the extracellular matrix of the lymph nodes, thus showing the potential to fabricate artificial lymph nodes for therapy and research models (organ on a chip).
High immune cell proliferation parameters have been obtained, essential to produce the necessary amounts of therapeutic T cells to reach the appropriate clinical doses.
The hydrogel can be used as a bioink for 3D printing, thus finding applications in biotechnology, medicine, and tissue engineering.
Stage of Development:
Under development/lab tested
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
European patent application (Priority date: May 21, 2020)
Suitable for International extension (PCT application)

Partner sought

Type and Role of Partner Sought:
The Spanish research center has a patent ready for licensing-out.

They are seeking industrial and research partners, either from the Biotech or Pharma sectors, to:

- Enter into preclinical R-Y-D collaboration (in vitro and/or in vivo drug testing)
- Further development until clinical proof-of-concept

The specific collaboration types will be:

· Industry for further development and/or license under license agreement.
· Research organization for collaborative and innovation projects under research cooperation agreement.
· Investor for financial support and/or setting-up of spin-off company under a joint venture agreement.

Client

Type and Size of Client:
R&D Institution
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
Spanish

Keywords

Technology Keywords:
06001024 Biomateriales médicos
06006004 Biopolímeros
03004007 Pharmaceutics
06001015 Productos farmacéuticos / medicamentos
06001013 Tecnología médica / ingeniería biomédica